Share This Page
Drug Price Trends for NDC 13668-0201
✉ Email this page to a colleague
Average Pharmacy Cost for 13668-0201
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 13668-0201
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 13668-0201
Introduction
The pharmaceutical landscape around NDC 13668-0201, a medication identified under the National Drug Code system, warrants a comprehensive market analysis, encompassing current positioning, competitive environment, regulatory status, and future pricing trends. This analysis provides vital insights for stakeholders including manufacturers, investors, healthcare providers, and policy analysts seeking data-driven projections.
Drug Profile and Regulatory Status
NDC 13668-0201 pertains to Ocrevus (ocrelizumab), a monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for treating multiple sclerosis (MS) — specifically relapsing forms and primary progressive MS. Developed by Genentech, a Roche subsidiary, Ocrevus has secured a significant market share owing to its efficacy and safety profile.
Ocrevus received FDA approval in March 2017 [1], with subsequent approvals expanding indications. The drug’s orphan status and approval for pivotal indications established a strong foothold in the disease-modifying therapies (DMTs) sector for MS.
Market Dynamics and Key Drivers
1. Epidemiological Trends:
MS affects approximately 2.8 million globally, with the U.S. accounting for roughly 1 million cases [2]. The prevalence continues to increase, driven by improved diagnostic techniques and demographic shifts. This rising prevalence directly correlates with increased demand for effective DMTs, including ocrelizumab.
2. Competitive Landscape:
Ocrevus competes with other high-efficacy MS therapies such as Tecfidera (dimethyl fumarate), Tysabri (natalizumab), and others like Mavenclad and Lemtrada. While some competitors present oral formulations, Ocrevus’s infusion route offers advantages in adherence and efficacy—though it also presents logistical and cost challenges.
3. Regulatory and Reimbursement Environment:
Pricing is influenced heavily by CMS reimbursement policies and negotiated payer discounts. Medicare Part B covers a significant portion of Ocrevus’s administration costs, but reimbursement rates and prior authorization requirements impact net revenue.
4. Market Penetration and Adoption:
Clinician preferences, patient tolerability, and insurance coverage impact Ocrevus uptake. Since its launch, sales have steadily increased, driven by expanded indications and clinical evidence supporting superior efficacy in primary-progressive MS.
Current Pricing Landscape
Official List Price:
As of 2023, the wholesale acquisition cost (WAC) for Ocrevus is approximately $7,000 per 300 mg dose, with treatment protocols typically involving two initial doses followed by maintenance doses every six months. For a standard annual course, the gross list price exceeds $57,000 per patient, considering multiple infusions [3].
Market-Driven Pricing Adjustments:
Pharmacy benefit managers (PBMs) and insurers negotiate substantial discounts off list prices, often ranging from 20-50%. These rebates significantly reduce payer costs and influence net revenues for Roche.
Reimbursement Trends:
Medicare and Medicaid negotiations and the advent of biosimilars (expected in upcoming years) could eventually exert downward pressure on prices, although biosimilar competition for ocrelizumab remains limited so far.
Projected Market and Price Trends
1. Market Expansion Projections:
The global MS therapeutics market is anticipated to reach USD 25 billion by 2027, CAGR of approximately 6.5% [4]. Ocrevus is expected to maintain a dominant position within high-efficacy therapies, capturing an increasing share through expanded indications and broader patient acceptance.
2. Impact of Biosimilars:
Although biosimilar versions of ocrelizumab are not yet available, regulatory pathways active in Europe and the U.S. suggest biosimilar entry could occur within 3-5 years. This development is poised to reduce prices by 20-40%, stimulating market competition and affordability.
3. Pricing Trajectory:
Initial unmet demand and high efficacy facilitated premium pricing; however, as biosimilars and value-based pricing models mature, the average net price for Ocrevus per unit is predicted to decline by approximately 15-25% over the next 3-5 years.
4. Policy and Market Forces:
Global health measures, such as price caps and increased negotiation power by payers, are likely to pressure manufacturers to sustain profitability through volume rather than premium pricing. Additionally, personalized medicine and biomarker-driven treatment selection could optimize utilization and improve cost-effectiveness, indirectly influencing pricing structures.
5. Potential for Value-Based Pricing:
Payers increasingly favor value-based arrangements, linking reimbursement levels to real-world effectiveness. Such models could modulate prices further, emphasizing outcomes and adherence over list prices.
Risks and Opportunities
- Risk of Price Erosion: Biosimilar entry and reimbursement pressure reduce profit margins.
- Pipeline Development: Roche’s ongoing research into next-generation anti-CD20 therapies could fortify its market position or introduce pricing flexibility.
- Regulatory Challenges: Future approvals for broader indications or novel combination therapies can expand the market but might also complicate pricing strategies.
Conclusion
NDC 13668-0201, representing Ocrevus, remains a high-value, high-demand drug within the MS treatment landscape. Its current premium pricing reflects its clinical efficacy, patent protections, and limited biosimilar competition. However, the evolving market—particularly biosimilar entry, policy reforms, and personalized medicine—will influence price trajectories, likely pushing net prices downward by mid-decade.
Stakeholders should monitor regulatory developments, pipeline progress, and payer negotiations to adapt their market strategies. The balance of innovation, market expansion, and cost-containment will shape Ocrevus’s pricing outlook in the coming years.
Key Takeaways
- The current list price for Ocrevus is around $7,000 per 300 mg dose, translating approximately to $57,000 annually per patient prior to discounts.
- Market growth is driven by increasing MS prevalence, expanding indications, and clinician adoption.
- Biosimilar competition, expected within 3-5 years, will exert significant downward pressure on prices, potentially reducing net prices by up to 25%.
- Payer strategies, including value-based agreements, are increasingly influencing pricing models.
- Monitoring regulatory and pipeline developments is essential to anticipate future market shifts and optimize pricing strategies.
FAQs
1. What factors primarily influence the pricing of NDC 13668-0201 (Ocrevus)?
Pricing is driven by clinical efficacy, manufacturing costs, regulatory exclusivity, market competition (including biosimilars), payer negotiations, and reimbursement policies.
2. How is the entry of biosimilars expected to impact Ocrevus's market price?
Biosimilar entry is projected to reduce the net price through increased competition, possibly by 20-40%, encouraging price adjustments and expanding access.
3. What segment of the MS market does Ocrevus target?
Ocrevus is targeted at relapsing MS forms and primary-progressive MS, capturing high-efficacy treatment needs.
4. How does the global MS prevalence influence Ocrevus's market potential?
Higher prevalence increases demand; with over 2.8 million cases worldwide, growth in diagnosed cases is expected to sustain and expand market opportunities.
5. What strategic considerations should stakeholders examine concerning Ocrevus's pricing?
Stakeholders should consider reimbursement trends, pipeline developments, biosimilar timelines, and evolving value-based pricing models to optimize positioning.
Sources
[1] FDA. Ocrevus (ocrelizumab) Prescribing Information. 2017.
[2] Multiple Sclerosis International Federation. Atlas of MS 3rd Edition. 2020.
[3] GoodRx. Ocrevus Price & Cost. 2023.
[4] Grand View Research. MS Therapeutics Market Size & Trends. 2022.
More… ↓
